The E7 oncogene is an essential tool used by papillomaviruses to interfere with the cell cycle and cellular differentiation. We investigated the effects of E7 expression on both cellular functions in skeletal muscle cells, a terminally differentiating system. When expressed in myoblasts, E7 impaired differentiation only partially, but allowed continuation of DNA synthesis during and after differentiation. Surprisingly, E7 expression in terminally differentiated myotubes could not reactivate DNA synthesis even though the oncogene bound the retinoblastoma protein, reduced its levels, and increased E2F transcriptional activity. Despite the high cyclin E protein levels induced by E7, the myotubes remained devoid of cyclin E-associated kinase activity. Enforcement of such activity in the presence of E7 brought myotubes into S phase. These results show that E7, unlike other DNA tumor-virus oncogenes, cannot reactivate the cell cycle in postmitotic myotubes. In contrast, E7 allows significant differentiation to occur in the presence of persisting DNA synthesis. These observations distinguish E7 from other functionally related oncogenes and bear significance for the understanding of the natural life cycle of human papillomaviruses. The fact that E7 alone inhibits the initiation but not the maintenance of the postmitotic state indicates that the mechanisms underlying these two functions are at least partially distinct.
Introduction
The E7 oncogene of human papillomaviruses (HPV E7) is essential for the viral life cycle as it plays a critical role in forcing the host cell to undergo DNA replication, a requirement for the virus to exploit the cell's DNA synthesis machinery for its own replication. This oncogene also encodes the major immortalizing and transforming activities of HPV (McMurray et al., 2001) .
The mechanistic bases of the E7 activities are not completely elucidated. However, E7 binds or otherwise affects a number of key regulatory proteins, including histone deacetylase 1 (Brehm et al., 1998) , the E and A cyclins (Martin et al., 1998) , the p21 cell cycle inhibitor (Jones et al., 1997) , and members of the AP-1 family of transcription factors (Antinore et al., 1996) , likely exerting its functions in part via these interactions. Prominent and best studied among the proteins bound by E7 are the retinoblastoma family of 'pocket' proteins. E7 plays its roles partly by binding the retinoblastoma protein (pRb) and the related p107 and p130 , presumably inactivating them, and promoting pRb degradation (Boyer et al., 1996; Berezutskaya et al., 1997) Although the HPV life cycle requires host-cell DNA replication, it also needs some degree of differentiation since the virus late promoter is only switched on in differentiated cells . HPV natural host cells belong to epithelia that undergo terminal differentiation, irreversibly preventing DNA replication. Thus, the virus must be able to force them to undertake DNA replication in the context of differentiation (McMurray et al., 2001) . This apparent paradox has been best studied, in vitro and in vivo, in keratinocytes (Jones et al., 1997) . The virus infects the basal epithelium, whence cells continually move into terminal differentiation. The infected cells, although showing the morphological features and a variety of markers of differentiation, are found to synthesize DNA. Whether the virus reactivates S phase in a terminally differentiated, postmitotic cell or keeps active the cell cycle of a differentiating cell is unclear. Indeed, the phenomenon is variably described as S phase reentry in postmitotic, differentiated cells (Jian et al., 1998; Chien et al., 2002) , maintenance of cells in a proliferative state in the course of differentiation (Kyo et al., 1997; Nguyen et al., 2002) or, perhaps most appropriately, left undecided (Jones et al., 1997) .
Similar observations have been made on skeletal muscle myoblasts expressing HPV E6 and E7 (Lochmuller et al., 1999) . When induced to differentiate, these cells fused into syncytial myotubes, but remained capable of undergoing DNA replication upon growth factor stimulation. However, this study too failed to determine whether the two oncogenes act by preventing growth arrest in the differentiating myoblasts or by allowing terminally differentiated myotubes to re-enter the cell cycle.
Skeletal muscle cells are a well-characterized example of terminal differentiation. In these cells, entry into the postmitotic state critically depends on pRb (Lipinski and Jacks, 1999), since Rb-defective myoblasts, much like E7-expressing ones (Lochmuller et al., 1999) , remain capable of replicating DNA even after differentiation (Schneider et al., 1994; Zacksenhaus et al., 1996) . As postmitotic cells, genetically intact myotubes are resistant to a variety of proliferative stimuli, including expression of retroviral oncogenes (Tiainen et al., 1996a) . However, a long series of experiments has established that some DNA tumor-virus oncogenes are able to reactivate the cell cycle in terminally differentiated cells. That is the case for polyoma (Fogel and Defendi, 1967; Yaffe and Gershon, 1967) and SV40 (Endo and Nadal-Ginard, 1989; Cardoso et al., 1993) Large T antigens and adenovirus E1A (Crescenzi et al., 1995; Tiainen et al., 1996b) . These oncogenes, while forcing postmitotic muscle cells to re-enter the cell cycle, suppress tissue-specific expression, in essence completely reverting the differentiation program (Tiainen et al., 1996b) . Since the Large T antigens and E1A share functional and structural similarities with HPV E7 , we asked whether the latter is able to reactivate the cell cycle in terminally differentiated skeletal muscle cells as well as the other DNA virus oncogenes.
We expressed HPV E7 into proliferating myoblasts or terminally differentiated myotubes. Similar to epithelial cells, E7-bearing myoblasts partially retained their capacity to differentiate and underwent differentiation while continuing to synthesize DNA. Surprisingly, E7 was unable to reactivate the cell cycle in terminally differentiated myotubes, even though it bound pRb, reduced its levels, and promoted E2F transcriptional activity. These results show that, at least in the skeletal muscle system, E7 is capable of maintaining cellular replication during differentiation, but is not able to reactivate postmitotic cells, setting it apart from other DNA virus oncogenes. In addition, our data indicate that the mechanisms initiating the postmitotic state are at least partially different from those maintaining it, and suggest that pRb plays a more important role in the former than in the latter.
Results

Expression of E7 in myoblasts prevents terminal differentiation
To examine the effects of E7 on skeletal muscle differentiation, C2C12 myoblasts were infected with either the LXSN-E7 or the LXSP-E7 retrovirus, bearing HPV type 16 E7. After appropriate drug selection, expression of the E7 oncoprotein by the resulting polyclonal cell lines (C2-LXSN-E7 and -LXSP-E7, respectively) was confirmed by Western blotting (Figure 1a) . The LXSN-infected cell line was seeded into soft-agar medium to assess anchorage-independent growth, a marker of cell transformation. Cells infected with the LXSN control virus, as expected, did not grow in suspension. In sharp contrast, on average 57.4% of the E7-expressing cells formed colonies in two experiments, demonstrating a strong anchorage independence.
To assess the effects of E7 on the differentiation program, the two cell lines were induced to differentiate by culturing them in serum-free (SF) medium. Both showed differentiation indices reduced to about 30% of that of control-infected cells (LXSP, Figure 1b) . In spite of impaired differentiation, about 20% of the E7-expressing cells differentiated and fused into multinucleated myotubes. Incubation of these myotubes with bromodeoxyuridine (BrdU) showed that most differentiated cells synthesized DNA (Figure 1c ): within a 24 h interval, 65% of the myotubes incorporated BrdU in SF medium and 90% did so in the presence of 10% fetal bovine serum (FBS). As expected, control myotubes did not incorporate BrdU (not shown).
Since E7 is known to induce pRb degradation, we determined the expression levels of pRb in differentiated cultures. Figure 1d shows that E7 strongly reduced the total amount of pRb protein in LXSP-E7 cells, as compared to both control myoblasts and myotubes, irrespective of its phosphorylation status.
These data show that E7 expression in C2C12 muscle cells impairs, but does not altogether block conversion into myotubes. However, the differentiation of E7 cells is not terminal, as it allows DNA synthesis, presumably as one result of strongly reduced pRb levels.
De novo E7 expression in terminally differentiated myotubes cannot reactivate DNA synthesis
To assess whether E7 is capable of inducing cell cycle reentry in terminally differentiated muscle cells, the oncogene must be introduced in myotubes formed in the absence of E7. Since postmitotic myotubes cannot be infected by conventional retroviruses, we constructed a recombinant adenovirus bearing HPV type 16 E7. Initial experiments were conducted with wild-type E7. However, to maximize expression of the oncogene, we devised a second adenovirus (Ad-FLAG-E7) expressing an HPV type 16 E7 cDNA FLAG tagged at its amino terminus. This particular molecule is significantly more stable than its wild-type version and possesses higher pRb degradation activity . As expected, the tagged molecule accumulated at higher levels than the wild-type (Figure 2a ; compare Ad-E7-and Ad-FLAG-E7-infected myotubes, in their respective blots, with LSXN-E7 myoblasts). Most experiments were carried out with both viruses, but the results were generally indistinguishable. For the sake of simplicity, only the experiments performed with the wild-type molecule will be shown.
C2C12 myotubes purified by the addition of cytosine b-d-arabinofuranoside (Ara-C, see Materials and methods) were infected with Ad-E7 at increasing multiplicity of infection (MOI). To detect DNA synthesis, the infected myotubes were incubated with BrdU for up to 72 h postinfection, in the presence or absence of serum. Unexpectedly, despite the high levels of E7, the myotubes did not incorporate BrdU at any time (Table 1) . This was not because of a general inability of our recombinant adenoviruses to reactivate the cell cycle in dormant cells, as 80% of serum-starved C3H-10T1/2 fibroblasts were readily induced to re-enter S phase upon infection with the same viruses (data not shown).
To assess whether, similar to E1A, E7 expression in myotubes affects the muscle differentiation program, Ad-E7-infected myotubes were analysed by Western blotting for muscle-specific myosin heavy chain (MyHC). In this experiment, as expected (Tiainen et al., 1996b) , the E1A-expressing dl520 adenovirus reduced MyHC levels. On the contrary, the E7-infected cells showed no reduction of MyHC ( Figure 2b ). The mRNA levels of myosin light chain (MLC), another muscle-specific gene, were also evaluated. Again, E7 expression produced no significant reduction in MLC levels ( Figure 2c ). Finally, we assessed the effect of expressing E7 in myotubes on the promoter of the muscle-specific creatine kinase (MCK). C2C12 cells were transiently transfected with an MCK-promoter luciferase reporter construct, then induced to differentiate in the presence of Ara-C. The purified myotubes thus obtained were infected with the appropriate adenoviruses and a luciferase assay was performed 48 h later. While E1A strongly reduced luciferase expression, Ad-E7 was comparable to the empty control virus, producing only a modest, nonspecific reduction ( Figure 2d , compare with control virus and see Tiainen et al., 1996a) in luciferase activity.
Altogether, these results lead us to the unanticipated conclusion that de novo E7 expression in myotubes affects neither the postmitotic state nor the expression of tissue-specific genes.
E7 shows multiple activities in terminally differentiated myotubes
The surprising inability of E7 to induce DNA synthesis or affect tissue-specific gene expression in terminally differentiated myotubes raised the concern that the oncogene was merely nonfunctional in the context of this cell type. To address this possibility, we looked at Figure 1 (a) Western blot analysis of E7 protein expression in two independent C2C12 cell lines. C2C12 myoblasts were infected with the control retrovirus LXSP or with either of two E7-carrying retroviruses, LXSN-E7 and LXSP-E7, respectively (l.c., loading control). (b) The three cell lines were cultured in SF medium for 3 days, and then subjected to immunofluorescence analysis for MyHC. The graph shows differentiation indices, calculated as percentages of nuclei in the culture belonging to MyHC-positive (differentiated) cells in three independent experiments; averages with standard deviation bars. (c) E7-expressing myotubes synthesize DNA. After inducing differentiation for 3 days, LXSP-E7 cells were shifted to medium containing 5% FBS for 24 h, then incubated in the presence of BrdU for 24 additional hours. The cultures were then fixed and stained by immunofluorescence for BrdU (green) and MyHC (red), a marker of terminal skeletal muscle differentiation. (d) Western blot analysis of pRb expression levels in differentiated cultures (myotubes, Mt) of E7-expressing and control C2C12 cells. The hypo-(pRb) and hyperphosphorylated forms (ppRb) of the protein are indicated. Proliferating myoblasts (Mb) are shown for comparison known functional consequences of E7 expression. First, the levels and phosphorylation status of pRb were studied in Ad-E7-infected myotubes. Figure 3a shows that E7 caused a significant reduction in pRb levels in the infected muscle cells, in comparison with both mockand control-infected myotubes, without inducing detectable phosphorylation. Infection with the E1A-expressing dl520 adenovirus, as previously shown (Tiainen et al., 1996b) , increased pRb levels and strongly induced phosphorylation of the protein. We conclude that E7 reduces pRb levels in myotubes as well as in myoblasts.
E7 is known to stimulate E2F activity both directly by binding E2F1 (Hwang et al., 2002) and indirectly, by inactivating pRb. Thus, we measured E2F transacting activity in E7-infected myotubes using an artificial reporter construct. E7 expression increased more than threefold the basal E2F activity in myotubes (Figure 3b) , making it comparable to that found in proliferating myoblasts or in myotubes infected with an E2F1-bearing adenovirus. Therefore, the ability of E7 to stimulate E2F activity is fully expressed in myotubes.
We also evaluated the effects of introducing E7 in myotubes on two cyclins critical for the G1 to S phase transition, cyclin E and cyclin A. As shown in Figure 3c , Ad-E7 infection induced myotubes to express cyclin E levels far higher than found in proliferating myoblasts and comparable to those induced by E2F1 or E1A. In contrast, E7 expression could increase the expression levels of cyclin A only modestly, if at all. In this respect, E7 behaved similarly to E2F1 but not E1A, the latter inducing a very strong expression of cyclin A in the infected myotubes.
We wished to determine whether the high levels of cyclin E induced by E7 corresponded to a proportionately strong kinase activity. Kinase assays were carried out on extracts from myotubes infected with E1A-, E2F1-, or E7-carrying viruses ( Figure 3d ). As expected (Pajalunga et al., 1999) , E1A induced an extremely high kinase activity while E2F, as already described (Pajalunga et al., 1999) , elicited no such activity in spite of similar levels of cyclin E. Similar to E2F1, E7 could not activate the cyclin E-associated kinase, suggesting a mechanistic explanation for its inability to induce cyclin A expression and DNA synthesis. Altogether, the results described in this paragraph show that E7 evokes a variety of responses in myotubes and that failure to induce DNA replication in these terminally differentiated cells is not the trivial result of inactivity of the oncogene in this cellular environment.
Complementing E7 with the cdk2 kinase triggers DNA synthesis in myotubes
The preceding results suggested that at least part of the inability of E7 to induce DNA synthesis in myotubes resides in its incompetence to activate the cdk2 kinase. Thus, we attempted a complementation experiment by expressing E7 along with cyclin E and cdk2. C2C12 myotubes were infected with recombinant adenoviruses expressing the three molecules. The cyclin E and cdk2 viruses were each used at MOI 200, conditions known to generate an extremely high kinase activity in myotubes (Latella et al., 2001 ). The two cell cycle regulators complemented E7 to induce DNA synthesis in 18% of the myotubes (an example is shown in Figure 4a ). The apparently low efficiency is because of the difficulty in achieving the optimal balance among the three exogenous molecules in every myotube using three viruses (Latella et al., 2001 ). However, it should be emphasized that the sole coexpression of cyclin E and cdk2 cannot trigger DNA synthesis in terminally differentiated muscle cells (Latella et al., 2001) , making the reactivation obtained with the triple infection highly significant. As a molecular correlate of S phase reactivation, the simultaneous expression of E7, cyclin E, and cdk2-induced phosphorylation of pRb to a higher degree than did cyclin E and cdk2 in the absence of E7 (Figure 4c) . Interestingly, overexpression of cyclin E and cdk2 appears to prevent E7-mediated pRb degradation (Figure 4c, last two lanes) . The molecular basis of this phenomenon are at present unclear.
Altogether, these results show that the failure of E7 to reactivate DNA synthesis in myotubes is because of its inability to induce cyclin E-associated kinase activity. Exogenous expression of such activity complements the action of E7, leading to DNA replication.
Discussion
The results presented in this paper show that, in the skeletal muscle system, E7 is capable of allowing DNA synthesis in differentiating cells, but cannot induce reentry into S phase of postmitotic, terminally differentiated cells. Thus, at least in this system our initial question, whether E7 keeps differentiating cells in the cell cycle or makes them re-enter into S phase after terminal differentiation has been established, is clearly answered in favor of the former possibility.
Consistent with its properties in epithelial cells, E7 does not altogether block differentiation, but prevents the terminal exit from the cell cycle that normally must precede it. Our retrovirus-infected C2C12 cell lines are transformed, as demonstrated by their remarkable anchorage-independent proliferation (Table 1 ), yet conserve the ability to differentiate to a significant degree. This finding underscores the peculiarity of E7, as skeletal muscle differentiation is exquisitely sensitive to oncogenic transformation and in fact expression of almost every oncogene completely blocks myogenesis (Alema' and Tato', 1994) . In particular, the polyoma (Maione et al., 1992) and SV40 (Tedesco et al., 1997) Large T antigens and adenovirus E1A (Webster et al., 1988) are powerful inhibitors of myogenic differentiation. Thus, its effects on skeletal muscle differentiation distinguish HPV E7 from other DNA virus oncogenes. The peculiar ability of E7 to uncouple growth arrest and differentiation in epithelial cells (Jones et al., 1997) , adipocytes (Muller et al., 1999) , and muscle cells (Lochmuller et al., 1999, and this paper) suggests that this oncogene acts through mechanisms finely tuned to preserve differentiation in spite of continuing DNA synthesis.
Our data strongly indicate that at least partially distinct mechanisms underline the terminal exit from the cell cycle of skeletal muscle cells and the maintenance of the postmitotic state thus acquired. Indeed, E7 can interfere with the initiation of the postmitotic state, but is no longer able to revert it once it is established. Therefore, the machinery E7 impinges upon are necessary for the establishment of the postmitotic state, but dispensable for its maintenance. A prominent mechanism of action of E7 is the binding, degradation, and inactivation of pRb. Our data indicate that E7 inactivates pRb equally well in myotubes and myoblasts, thus suggesting that pRb, although absolutely required to initiate the postmitotic state, is dispensable for its preservation. This possibility, which cannot be proved by the data presented here, is currently under scrutiny.
The inability of E7 to reactivate the cell cycle in terminally differentiated myotubes is explained by its The myotubes were then left in SF medium or shifted to medium containing 5% FBS and subjected to Western blot analysis for pRb 48 h after infection incompetence to induce cyclin E-associated kinase activity in these cells. Our experiments show that E7 induces high levels of cyclin E in myotubes, but no measurable attached kinase activity. Increased expression of cyclin E and its associated kinase activity is found in E7-reactivated quiescent cells (Zerfass et al., 1995) , and in E7-expressing fibroblasts (Martin et al., 1998) . Cyclin E-associated kinase activity is necessary for progression of the cell cycle into S phase (Ohtsubo et al., 1995) and is required for the expression of cyclin A (Zerfass-Thome et al., 1997) , also indispensable for cell cycle progression (Pagano et al., 1992) . Accordingly, since neither E7 nor E2F are able to activate the cyclin E-associated kinase, cyclin A is not induced in E7-or E2F1-expressing myotubes (Figure 3c) .
That the incompetence of E7 to trigger DNA synthesis in myotubes is because of the absence of the cyclin E kinase is demonstrated by the fact that enforcing this activity is sufficient to induce S phase in myotubes. These results are entirely consistent with data previously reported by our group and others, showing that myotubes cannot be reactivated by forced expression of either E2F (Puri et al., 1998; Pajalunga et al., 1999) or cyclin E (Latella et al., 2001) . Accordingly, E7 is capable of eliciting significant E2F activity in myotubes but, in the absence of complementary cyclin E-associated kinase activity, E2F is insufficient to induce DNA synthesis in these cells. The combined activities of E2F and cyclin E coerce myotubes into S phase, explaining the different sensitivity of quiescent and terminally differentiated cells to E7 with the resistance of the latter cells to activate the cyclin E kinase. The molecular underpinnings of such resistance will be the subject of a future investigation.
Materials and methods
Cells
The murine C2C12 myoblast cell line (Blau et al., 1985) was cultured in DMEM medium supplemented with 10% FBS. Differentiation was induced by starving the cells in SF medium (Tiainen et al., 1996b) for 72 h. Pure cultures of C2C12 myotubes were obtained by adding 50 mm Ara-C to SF medium in the first 48 h to eliminate undifferentiated cells, then removing it between 48 and 72 h. Ara-C-purified myotubes routinely contained more than 90% of the nuclei in the culture. Anchorage independence tests were performed as described (Bignami et al., 1988) .
Adenoviruses
The Ad-cdk2, Ad-cycE and Ad-E2F1 recombinant adenoviruses have been previously described (Leone et al., 1999) . In all experiments, the empty control virus was J-pCA13 (Pajalunga et al., 1999) . The Ad-FLAG-E7 and Ad-wt E7 viruses were generated using the method devised by He et al. (1998) . The dl520 virus is a deletion mutant of human adenovirus type 5, expressing 12S but not 13S E1A (Haley et al., 1984) . All recombinant adenoviruses except dl520, independent of the construction method, express their respective cDNAs under the control of the cytomegalovirus immediate-early promoter/enhancer. All replication-defective, recombinant adenoviruses were grown and titrated in the permissive 293 cell line.
Retroviruses
The LXSN-E7 virus is produced by the PA317 LXSN 16E7 cell line (ATCC cell line CRL-2205). LXSP-E7 was constructed by cloning an HPV-16 E7 cDNA into the filled-in EcoRI site of the LXSP plasmid, a version of LXSN bearing the puromycin resistance gene (a kind gift of S Soddu). All retroviruses were grown in the ecotropic Phoenix packaging cell line and titrated on NIH3T3 fibroblasts.
Immunofluorescence
The following mAbs or antisera were used for immunofluorescence. mAb Bu20a to 5-bromo-2 0 -deoxyuridine (BrdU, Dako); rabbit antiserum to muscle-specific MyHC (a kind gift of G Cossu). mAbs were detected by a FITC-conjugated, affinity-purified, goat serum anti-mouse immunoglobulin G (Organon Teknika). Reaction of rabbit antisera was detected by a TRITC-conjugated, affinity-purified, goat serum antirabbit immunoglobulin G (Organon Teknika). After immunofluorescence treatments, nuclei were stained by a 3-min incubation in a 0.1-mg/ml solution of Hoechst 33258 dye in phosphate-buffered saline.
Western blot analysis
Whole-cell extracts were obtained by disrupting cells in lysis buffer (50 mm Tris-HCl, pH 8, 150 mm NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP40, 1 mm EDTA, 5 mg/ml leupeptin, 5 mg/ml aprotinin, 5 mg/ml pepstatin). To extract pRb, a high-salt buffer was used (50 mm Tris-HCl, 250 mm NaCl, 5 mm EDTA, 0.1% Triton X-100, 50 mm NaF, 0.1 mm sodium orthovanadate, protease inhibitors as above). Protein extracts were separated by SDS-PAGE and electroblotted onto a nitrocellulose (Schleicher and Schuell) or PVDF (Millipore, for E7 blots) membrane. Proteins were analysed with the following antibodies: rabbit antiserum M-20 to cyclin E (Santa Cruz); rabbit antiserum C-19 to cyclin A (Santa Cruz); mAb clone G3-245 to pRb (Pharmingen); mAb clone 8C9 to HPV16-E7 (Zymed Laboratories). Loading controls were provided by Hsp70 (mAb clone N27F3-4, StressGeb Biotechnologies), b-tubulin (mAb clone 2-28-33, Sigma), or nonspecific bands. Immunoreactions were detected with peroxidase-conjugated secondary antibodies and a chemiluminescent substrate (BioRad).
Immunoprecipitation and kinase activity assay
Cyclin E-associated kinase activity was determined as previously described (Pajalunga et al., 1999) using the M-20 rabbit antiserum to precipitate mouse cyclin E (Santa Cruz).
Northern blot analysis
For extraction of total cellular RNA, 2 Â 10 6 C2C12 cells were plated into 100-mm diameter dishes, induced to differentiate, and infected as described above. Samples of 15-20 mg were run on formaldehyde gels, transferred, blotted, and hybridized according to standard protocols. A full-length cDNA was used as a probe for GAPDH. For MLC-1 the first exon of the gene was used as a probe.
Luciferase assays
Reporter constructs: pGL3TATAbasic and pGL3TATAba-sic6XE2F-Luc (derived from pGL3basic, Promega) bear the E1B TATA box or six E2F DNA binding sites, respectively, upstream of a luciferase cDNA. A CMV-b-Gal vector was used to normalize for transfection efficiency. The MCKLuc plasmid bears the MCK promoter upstream of a luciferase cDNA (Porrello et al., 2000) . C2C12 myoblasts were transfected with the appropriate reporter constructs and induced to differentiate 48 h later. The derived myotubes were infected with recombinant adenoviruses 72 h later and collected after further 48 h. Luciferase and b-galactosidase assays were carried out by standard techniques.
